Small-molecule correctors and stabilizers to target p53

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The tumor suppressor p53 is frequently mutated in human cancers, making it a critical target for precision oncology.
• Cancer cells inactivate p53 through TP53 mutations or accelerated protein degradation.
• Restoring p53 function is a promising strategy to inhibit tumor initiation and progression.

Purpose of the Study:

• To review novel and repurposed compounds targeting the p53 pathway.
• To discuss the mechanisms of action for MDM2 antagonists and mutant p53 correctors.
• To examine the clinical challenges associated with p53-targeting therapies.

Main Methods:

• Literature review of p53-targeting compounds, focusing on MDM2 inhibitors and mutant p53 correctors.
• Analysis of compound mechanisms: MDM2 inhibitors prevent p53 degradation; correctors enhance mutant p53 stability.
• Exploration of therapeutic strategies and clinical translation hurdles for p53-based treatments.

Main Results:

• MDM2 antagonists reactivate p53 by inhibiting its degradation.
• Mutant p53 correctors aim to restore the tumor-suppressive activity of mutated p53 proteins.
• Both approaches present unique challenges for clinical development and application.

Conclusions:

• Targeting p53 via MDM2 inhibition or mutant p53 correction offers significant therapeutic potential in oncology.
• Overcoming challenges in drug delivery, specificity, and clinical efficacy is crucial for advancing these p53-targeting agents.
• Further research into novel and repurposed compounds is essential for effective cancer treatment strategies.